SIONNA

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function... Our team has deep experience in CF drug development and other rare diseases, strong ties to the CF community, experience building best-in-class companies and above all, an unrelenting determination to improve the future of those impacted by CF... We're developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function.

Primary location: Waltham United States